Verve-102
-
Verve-102 Gene Therapy Demonstrates Significant LDL-C Reduction in Phase 1b Trial
New clinical data from the Heart-2 trial reveals that a single dose of the gene therapy VERVE-102 can reduce ‘bad’ cholesterol by up to 62%, marking a potential shift from chronic cardiovascular management to one-time intervention.